title: Serum amyloid A, C-reactive protein and remnant-like lipoprotein particle cholesterol in type 2 diabetic patients with coronary heart disease.
abstract: BACKGROUND
  Serum amyloid A (SAA) and C-reactive protein (CRP) have been suggested to be involved in the process of coronary heart disease (CHD) and to be potential markers and/or predictors of CHD. Remnant-like lipoprotein particles (RLPs), which are regarded as atherogenic remnant lipoprotein, are reported to be increased in type 2 diabetic patients. We assessed the association of CHD with SAA, CRP and RLP-cholesterol in type 2 diabetic patients.
  
  
  METHODS
  One hundred and twenty-six diabetic patients without CHD and 41 patients with CHD were recruited from our hospital. Plasma SAA was measured by the latex agglutination nephelometric immunoassay. Plasma high-sensitivity CRP was measured by a latex immunoturbidity method. Plasma RLP-cholesterol was measured by an immunoabsorption enzyme method.
  
  
  RESULTS
  The mean standard deviation values of RLP-cholesterol in patients with and without CHD were 0.22 (0.26) mmol/L and 0.15 (0.10) mmol/L, respectively (P <0.05). Median (interquartile ranges) for SAA in patients with and without CHD were 7.4 (4.2-11.2) mg/L and 3.9 (2.2-5.9) mg/L, respectively (P <0.001). Median (interquartile ranges) for CRP in patients with and without CHD was 1.14 (0.45-2.08) mg/L and 0.43 (0.19-1.25) mg/L, respectively (P <0.001). For all patients, the Spearman rank correlation statistics for RLP-cholesterol compared with SAA and with CRP were 0.213 (P <0.05) and 0.301 (P <0.01), respectively.
  
  
  CONCLUSIONS
  These data suggest that SAA, CRP and RLP-cholesterol are increased in type 2 diabetic patients with CHD, and that the inflammatory proteins correlate with remnant lipoprotein.
authors.affiliation: Clinical Laboratory, Kawasaki Medical School, Kurashiki 701-0192, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hamano
authors.forename: M
authors.initials: M
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Eto
authors.forename: S
authors.initials: S
authors.lastname: Nishimatsu
authors.forename: H
authors.initials: H
authors.lastname: Suda
authors.forename: M
authors.initials: M
authors.lastname: Matsuda
authors.forename: M
authors.initials: M
authors.lastname: Matsuki
authors.forename: S
authors.initials: S
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Kaku
mesh_terms: D000368:Aged; D015415:Biomarkers; D002097:C-Reactive Protein / Q000032:analysis*; D002784:Cholesterol / Q000097:blood*; D003327:Coronary Disease / Q000097:blood* / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D005260:Female; D006801:Humans; D007841:Latex Fixation Tests; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009391:Nephelometry and Turbidimetry; D000685:Serum Amyloid A Protein / Q000032:analysis*; D014280:Triglycerides / Q000097:blood*
chemical_list: D015415:Biomarkers; D008074:Lipoproteins; D000685:Serum Amyloid A Protein; D014280:Triglycerides; C112017:remnant-like particle cholesterol; D002097:C-Reactive Protein; D002784:Cholesterol